Curative radiation for orbital MZL: how much?

In this issue of Blood, Desai et al report a large retrospective analysis from the University of Miami including 182 patients with primary ocular adnexal mucosa-associated lymphoid tissue (MALT) lymphoma (orbital marginal zone lymphoma [MZL]).1 Most were at an early stage (82%), and 76% were treated successfully with orbital irradiation. Treatment and follow-up data spanned 31 years. This study reaffirms the excellent long-term control of orbital MZL with localized radiation therapy (RT; complete remission [CR] rate >97%); only 3 deaths were attributed to lymphoma, and 2 of those occurred following systemic transformation.